Coronary microvascular dysfunction: Sex-specific risk, diagnosis, and therapy

Nature Reviews Cardiology

Volumn 12, Issue 7, 2015, Pages 406-414

  Dean, Jenna ^a   Cruz, Sherwin Dela ^a   Mehta, Puja K ^a   Merz, C Noel Bairey ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IVABRADINE; NICORANDIL; NITRIC ACID DERIVATIVE; PHOSPHODIESTERASE V INHIBITOR; RANOLAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; XANTHINE DERIVATIVE;

ANGIOCARDIOGRAPHY; AUTOGENIC TRAINING; CARDIOVASCULAR MAGNETIC RESONANCE; COGNITIVE THERAPY; CORONARY ARTERY DISEASE; CORONARY FLOW RESERVE; CORONARY MICROVASCULAR DYSFUNCTION; ENDOTHELIAL DYSFUNCTION; HEART MUSCLE ISCHEMIA; HEART REHABILITATION; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MEDITERRANEAN DIET; NERVE STIMULATION; NON INVASIVE PROCEDURE; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SEX DIFFERENCE; SMOKING CESSATION; SPINAL CORD STIMULATION; TRANSTHORACIC ECHOCARDIOGRAPHY; CORONARY ARTERY BLOOD FLOW; FEMALE; MALE; MICROCIRCULATION; MYOCARDIAL ISCHEMIA; PATHOPHYSIOLOGY; PHYSIOLOGY;

CORONARY ARTERY DISEASE; CORONARY CIRCULATION; FEMALE; HUMANS; MALE; MICROCIRCULATION; MYOCARDIAL ISCHEMIA; PROGNOSIS; RISK FACTORS; SEX FACTORS;

EID: 84931955878     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2015.72     Document Type: Review

References (154)

1. Fihn, S. D. et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 130, 1749-1767 (2014).
2. Montalescot, G. et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur. Heart J. 34, 2949-3003 (2013).
3. Banks, K., Lo, M. & Khera, A. Angina in women without obstructive coronary artery disease. Curr. Cardiol. Rev. 6, 71-81 (2010).
4. Sullivan, A. Chest pain in women: clinical, investigative & prognostic features. BMJ 308, 4 (1994).
5. Shaw, L. J. et al. Insights from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) study: part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J. Am. Coll. Cardiol. 47 (Suppl.), S4-S20 (2006).
6. Bairey Merz, C. N. et al. Insights from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) study: part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J. Am. Coll. Cardiol. 47 (Suppl.), S21-S29 (2006).
7. Bugiardini, R. & Bairey Merz, C. N. Angina with normal coronary arteries: a challenging philosophy. JAMA 293, 477-484 (2005).
8. Gulati, M. et al. Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. Arch. Intern. Med. 169, 843-850 (2009).
9. Eastwood, J. A. et al. Anginal symptoms, coronary artery disease, and adverse outcomes in black and white women: the NHLBI-sponsored Women's Ischemia Syndrome Evaluation study. J. Womens Health 22 724-732 (2013).
10. Johnson, B. D. et al. Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: results from the NIH-NHLBI-sponsored Women's Ischaemia Syndrome Evaluation (WISE) study. Eur. Heart J. 27, 1408-1415 (2006).
11. Reis, S. E. et al. Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study. Am. Heart J. 141, 735-741 (2001).
12. Kothawade, K. & Bairey Merz, C. N. Microvascular coronary dysfunction in women: pathophysiology, diagnosis, and management. Curr. Probl. Cardiol. 36, 27 (2011).
13. Sharaf, B. et al. Adverse outcomes among women presenting with signs and symptoms of ischemia and no obstructive coronary artery disease: findings from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) angiographic core laboratory. Am. Heart J. 166, 134-141 (2013).
14. Sedlak, T. L. et al. Sex differences in clinical outcomes in patients with stable angina and no obstructive coronary artery disease. Am. Heart J. 166, 38-44 (2013).
15. Jespersen, L. et al. Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events. Eur. Heart J. 33, 734-744 (2012).
16. Maddox, T. M. et al. Nonobstructive coronary artery disease and risk of myocardial infarction. JAMA 312, 1754-1763 (2014).
17. Humphries, K. H., Pu, A., Gao, M., Carere, R. G. & Pilote, L. Angina with normal coronary arteries: sex differences in outcomes. Am. Heart J. 155, 375-381 (2008).
18. Jones, E., Eteiba, W. & Bairey Merz, N. Cardiac syndrome X and microvascular coronary dysfunction. Trends Cardiovasc. Med. 22, 161-168 (2012).
19. Murthy, V. L. et al. Effects of sex on coronary microvascular dysfunction and cardiac outcomes. Circulation 129, 2518-2527 (2014).
20. Camici, P. G. & Crea, F. Coronary microvascular dysfunction. N. Engl. J. Med. 356, 830-840 (2007).
21. Arrebola-Moreno, A. L. et al. Coronary microvascular spasm triggers transient ischemic left ventricular diastolic abnormalities in patients with chest pain and angiographically normal coronary arteries. Atherosclerosis 236, 207-214 (2014).
22. Davis, K. B., Chaitman, B., Ryan, T., Bittner, V. & Kennedy, J. W. Comparison of 15-year survival for men and women after initial medical or surgical treatment for coronary artery disease: a CASS registry study. Coronary Artery Surgery Study. J. Am. Coll. Cardiol. 25, 1000-1009 (1995).
23. Shaw, L. J. et al. The economic burden of angina in women with suspected ischemic heart disease: results from the National Institutes of Health-National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. Circulation 114, 894-904 (2006).
24. Shaw, L. J. et al. Impact of ethnicity and gender differences on angiographic coronary artery disease prevalence and in-hospital mortality in the American College of Cardiology-National Cardiovascular Data Registry. Circulation 117, 1787-1801 (2008).
25. Johnston, N., Schenck-Gustafsson, K. & Lagerqvist, B. Are we using cardiovascular medications and coronary angiography appropriately in men and women with chest pain? Eur. Heart J. 32, 1331-1336 (2011).
26. Pepine, C. J. et al. Some thoughts on the vasculopathy of women with ischemic heart disease. J. Am. Coll. Cardiol. 47 (Suppl.), S30-S35 (2006).
27. Erbel, R. et al. Value of intracoronary ultrasound and Doppler in the differentiation of angiographically normal coronary arteries: a prospective study in patients with angina pectoris. Eur. Heart J. 17, 880-889 (1996).
28. Mieres, J. H. et al. Signs and symptoms of suspected myocardial ischemia in women: results from the What is the Optimal Method for Ischemia Evaluation in WomeN? trial. J. Womens Health 20, 1261-1268 (2011).
29. Safdar, B. et al. Gender-specific research for emergency diagnosis and management of ischemic heart disease: proceedings from the 2014 Academic Emergency Medicine Consensus Conference Cardiovascular Research Workgroup. Acad. Emerg. Med. 21, 1350-1360 (2014).
30. Masseri, A., Crea, F., Kaski, J. C. & Crake, T. Mechanisms of angina pectoris in syndrome X. J. Am. Coll. Cardiol. 17, 499-506 (1991).
31. Herrmann, J., Kaski, J. C. & Lerman, A. Coronary microvascular dysfunction in the clinical setting: from mystery to reality. Eur. Heart J. 33, 2771-2783 (2012).
32. Eggers, K. M., Johnston, N., James, S., Lindahl, B. & Venge, P. Cardiac troponin I levels in patients with non-ST-elevation acute coronary syndrome-The importance of gender. Am. Heart J. 168, 317-324.e1 (2014).
33. Crea, F., Camici, P. G. & Bairey Merz, C. N. Coronary microvascular dysfunction: an update. Eur. Heart J. 1101-1111 (2013).
34. Wessel, T. R. et al. Coronary microvascular reactivity is only partially predicted by atherosclerosis risk factors or coronary artery disease in women evaluated for suspected ischemia: results from the NHLBI Women's Ischemia Syndrome Evaluation (WISE). Clin. Cardiol. 30, 69-74 (2007).
35. Suessenbacher, A. et al. Sex differences in independent factors associated with coronary artery disease. Wien. Klin. Wochenschr. 126, 718-726 (2014).
36. Huxley, R. R. & Woodward, M. Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-Analysis of prospective cohort studies. Lancet 378, 1297-1305 (2011).
37. Almdal, T., Scharling, H., Jensen, J. S. & Vestergaard, H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13, 000 men and women with 20 years of follow-up. Arch. Intern. Med. 164, 1422-1426 (2004).
38. Moreau, P., d'Uscio, L. & Lüscher, T. F. Structure and reactivity of small arteries in aging. Cardiovasc. Res. 37, 247-253 (1998).
39. Michel, J. B. et al. Effect of chronic ANG 1-coverting enzyme inhibitors on aging processes. II. Large arteries. Am. J. Physiol. 267 (Pt 2), R124-R135 (1994).
40. Rizzoni, D. et al. Relationships between coronary flow vasodilator capacity and small artery remodelling in hypertensive patients. J. Hypertens. 21, 625-631 (2003).
41. Mundhenke, M., Schwartzkopff, B. & Strauer, B. E. Structural analysis of arteriolar and myocardial remodelling in the subendocardial region of patients with hypertensive heart disease and hypertrophic cardiomyopathy. Virchows Arch. 431, 265-273 (1997).
42. Agabiti-Rosel, E. Structural and functional changes of the microcirculation in hypertension: influence of pharmacological therapy. Drugs 63, 19-29 (2003).
43. Smith, S. M. et al. Cardiovascular and mortality risk of apparent resistant hypertension in women with suspected myocardial ischemia: a report from the NHLBI-sponsored WISE study. J. Am. Heart Assoc. 3, e000660 (2014).
44. Sucato, V. Evola, S., Novo, G. & Novo, S. Diagnosis of coronary microvascular dysfunction in diabetic patients with cardiac syndrome X: comparison by current methods [Italian]. Recenti Prog. Med. 104, 63-68 (2013).
45. Girach, A. & Vignati, L. Diabetic microvascular complications-can the presence of one predict the development of another? J. Diabetes Complications 20, 228-237 (2006).
46. Di Carli, M. F., Janisse, J., Grunberger, G. & Ager, J. Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J. Am. Coll. Cardiol. 41, 2387-2393 (2003).
47. Galderisi, M. et al. Coronary flow reserve in hypertensive patients with hypercholesterolemia and without coronary heart disease. Am. J. Hypertens. 20, 177-183 (2007).
48. Duvernoy, C. S. et al. Gender differences in myocardial blood flow dynamics: lipid profile and hemodynamic effects. J. Am. Coll. Cardiol. 33, 463-470 (1999).
49. Bonetti, P. O., Lerman, L. O. & Lerman, A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler. Thromb. Vasc. Biol. 23, 168-175 (2003).
50. Recio-Mayoral, A., Rimoldi, O. E., Camici, P. G. & Kaski, J. C. Inflammation and microvascular dysfunction in cardiac syndrome X patients without conventional risk factors for coronary artery disease. JACC Cardiovasc. Imaging 6, 660-667 (2013).
51. Lanza, G. A. et al. Assessment of systemic inflammation and infective pathogen burden in patients with cardiac syndrome X. Am. J. Cardiol. 94, 40-44 (2004).
52. Cosin-Sales, J., Pizzi, C., Brown, S. & Kaski, J. C. C-reactive protein, clinical presentation, and ischemic activity in patients with chest pain and normal coronary angiograms. J. Am. Coll. Cardiol. 41, 1468-1474 (2003).
53. Ishimori, M. et al. Myocardial ischemia in the absence of obstructive coronary artery disease in systemic lupus erythematosus. JACC Cardiovasc. Imaging 4, 27-33 (2011).
54. Caliskan, M. et al. Impaired coronary microvascular and left ventricular diastolic functions in patients with ankylosing spondylitis. Atherosclerosis 196, 306-312 (2008).
55. Reriani, M. et al. Microvascular endothelial dysfunction predicts the development of erectile dysfunction in men with coronary atherosclerosis without critical stenoses. Coron. Artery Dis. 25, 552-557 (2014).
56. Kaski, J. C. Cardiac syndrome X in women: the role of oestrogen deficiency. Heart 92 (Suppl. 3), iii5-iii9 (2006).
57. Rosano, G. M. et al. 17-beta-estradiol therapy lessens angina in postmenopausal women with syndrome X. J. Am. Coll. Cardiol. 28, 1500-1505 (1996).
58. Albertsson, P. A., Emanuelsson, H. & Milsom, I. Beneficial effect of treatment with transdermal estradiol-17-beta on exercise-induced angina and ST segment depression in syndrome X. Int. J. Cardiol. 54, 13-20 (1996).
59. Adamson, D. L., Webb, C. M. & Collins, P. Esterified estrogens combined with methyltestosterone improve emotional well-being in postmenopausal women with chest pain and normal coronary angiograms. Menopause 8, 233-238 (2001).
60. Mosca, L. et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association. Circulation 123, 1243-1262 (2011).
61. Merz, C. N. et al. A randomized controlled trial of low-dose hormone therapy on myocardial ischemia in postmenopausal women with no obstructive coronary artery disease: results from the National Institutes of Health/National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE). Am. Heart J. 159, 987.e1-e7 (2010).
62. Lanza, G. A. & Crea, F. Primary coronary microvascular dysfunction: clinical presentation, pathophysiology, and management. Circulation 121, 2317-2325 (2010).
63. Mehta, P. K. et al. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease. JACC Cardiovasc. Imaging 4, 514-522 (2011).
64. Camici, P. G., d'Amati, G. & Rimoldi, O. Coronary microvascular dysfunction: mechanisms and functional assessment. Nat. Rev. Cardiol. 12, 48-62 (2015).
65. McArdle, B. et al. Cardiac PET: metabolic and functional imaging of the myocardium. Semin. Nucl. Med. 43, 434-448 (2013).
66. Gould, K. L. et al. Anatomic versus physiologic assessment of coronary artery disease: role of coronary flow reserve, fractional flow reserve, and positron emission tomography imaging in revascularization decision-making. J. Am. Coll. Cardiol. 62, 1639-1653 (2013).
67. Valenta, I., Dilsizian, V., Quercioli, A., Ruddy, T. D. & Schindler, T. H. Quantitative PET/CT measures of myocardial flow reserve and atherosclerosis for cardiac risk assessment and predicting adverse patient outcomes. Curr. Cardiol. Rep. 15, 344 (2013).
68. Plank, F. et al. The diagnostic and prognostic value of coronary CT angiography in asymptomatic high-risk patients: a cohort study. Open Heart 1, e000096 (2014).
69. Hou, Z. H. et al. Prognostic value of coronary CT angiography and calcium score for major adverse cardiac events in outpatients. JACC Cardiovasc. Imaging 5, 990-999 (2012).
70. [No authors listed] Italian Society of Cardiovascular Echography (SIEC) Consensus Conference on the state of the art of contrast echocardiography. Ital. Heart J. 5, 309-334 (2004).
71. Pathan, F. & Marwick, T. H. Myocardial perfusion imaging using contrast echocardiography. Prog. Cardiovasc. Dis. http://dx.doi.org/10.1016/j.pcad.2015.03.005.
72. Bartel, T. et al. Noninvasive assessment of microvascular function in arterial hypertension by transthoracic Doppler harmonic echocardiography. J. Am. Coll. Cardiol. 39, 2012-2018 (2002).
73. Prescott, E. et al. Improving diagnosis and treatment of women with angina pectoris and microvascular disease: the iPOWER study design and rationale. Am. Heart J. 167, 452-458 (2014).
74. Caiati, C. et al. Validation of a new noninvasive method (contrast-enhanced transthoracic second harmonic echo Doppler) for the evaluation of coronary flow reserve: comparison with intracoronary Doppler flow wire. J. Am. Coll. Cardiol. 34, 1193-1200 (1999).
75. Meimoun, P. et al. Transthoracic coronary flow velocity reserve assessment: comparison between adenosine and dobutamine. J. Am. Soc. Echocardiogr. 19, 1220-1228 (2006).
76. Dimitrow, P. P. Transthoracic Doppler echocardiography-noninvasive diagnostic window for coronary flow reserve assessment. Cardiovasc. Ultrasound 1, 4 (2003).
77. Okayama, H. et al. Usefulness of an echo-contrast agent for assessment of coronary flow velocity and coronary flow velocity reserve in the left anterior descending coronary artery with transthoracic Doppler scan echocardiography. Am. Heart J. 143, 668-675 (2002).
78. Pizzuto, F. et al. Assessment of flow velocity reserve by transthoracic Doppler echocardiography and venous adenosine infusion before and after left anterior descending coronary artery stenting. J. Am. Coll. Cardiol. 38, 155-162 (2001).
79. Ueno, Y., Nakamura, Y., Takashima, H., Kinoshita, M. & Soma, A. Noninvasive assessment of coronary flow velocity and coronary flow velocity reserve in the right coronary artery by transthoracic Doppler echocardiography: comparison with intracoronary Doppler guidewire. J. Am. Soc. Echocardiogr. 15, 1074-1079 (2002).
80. Panting, J. R. et al. Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. N. Engl. J. Med. 346, 1948-1953 (2002).
81. Shufelt, C. L. et al. Cardiac magnetic resonance imaging myocardial perfusion reserve index assessment in women with microvascular coronary dysfunction and reference controls. Cardiovasc. Diagn. Ther. 3, 153-160 (2013).
82. Doyle, M. et al. Prognostic value of global MR myocardial perfusion imaging in women with suspected myocardial ischemia and no obstructive coronary disease: results from the NHLBI-sponsored WISE (Women's Ischemia Syndrome Evaluation) study. JACC Cardiovasc. Imaging 3, 1030-1036 (2010).
83. Freed, B. H. et al. Prognostic value of normal regadenoson stress perfusion cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson. 15, 108 (2013).
84. Dez Prez, R. D. et al. Cost-effectiveness of myocardial perfusion imaging: a summary of the currently available literature. J. Nucl. Cardiol. 12, 750-759 (2005).
85. Mishra, J. P., Acio, E., Heo, J., Narula, J. & Iskandrian, A. E. Impact of stress single-photon emission computed tomography perfusion imaging on downstream resource utilization. Am. J. Cardiol. 83, 1401-1403 (1999).
86. McCrohon, J. A. et al. Adjunctive role of cardiovascular magnetic resonance in the assessment of patients with inferior attenuation on myocardial perfusion SPECT. J. Cardiovasc. Magn. Reson. 7, 377-382 (2005).
87. Wei, J. et al. Safety of coronary reactivity testing in women with no obstructive coronary artery disease: results from the NHLBI-sponsored WISE (Women's Ischemia Syndrome Evaluation) study. JACC Cardiovasc. Interv. 5, 646-653 (2012).
88. Prasad, A. et al. Abnormal coronary microvascular endothelial function in humans with asymptomatic left ventricular dysfunction. Am. Heart J. 146, 549-554 (2003).
89. Pepine, C. J. et al. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) study. J. Am. Coll. Cardiol. 55, 2825-2832 (2010).
90. Suwaidi, J. A. et al. Long-Term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101, 948-954 (2000).
91. Kuruvilla, S. & Kramer, C. M. Coronary microvascular dysfunction in women: on overview of diagnostic strategies. Expert Rev. Cardiovasc. Ther. 11, 1515-1525 (2013).
92. Gibson, C. M. et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 93, 879-888 (1996).
93. Manginas, A. et al. Estimation of coronary flow reserve using the Thrombolysis In Myocardial Infarction (TIMI) frame count method. Am. J. Cardiol. 83, 1562-1565 (1999).
94. Petersen, J. W. et al. TIMI frame count and adverse events in women with no obstructive coronary disease: a pilot study from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE). PLoS ONE 9, e96630 (2014).
95. Luo, C. et al. Thermodilution-derived coronary microvascular resistance and flow reserve in patients with cardiac syndrome X. Circ. Cardiovasc. Interv. 7, 43-48 (2014).
96. Fearon, W. F. et al. Comparison of coronary thermodilution and Doppler velocity for assessing coronary flow reserve. Circulation 108, 2198-2200 (2003).
97. von Mering, G. O. et al. Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: results from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 109, 722-725 (2004).
98. Schlächinger, V., Britten, M. B., Zeiher, A. M. Prognostic impact of coronary vasodilator dysfunction on adverse long-Term outcome of coronary heart disease. Circulation 101, 1899-1906 (2000).
99. Taqueti, V. R. et al. Interaction of impaired coronary flow reserve and cardiomyocyte injury on adverse cardiovascular outcomes in patients without overt coronary artery disease. Circulation 131, 528-535 (2015).
100. Taqueti, V. R. et al. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. Circulation 131, 19-27 (2015).
101. Demirkol, S. et al. Association between microvascular angina and erectile dysfunction. Int. J. Impot. Res. 26, 124-127 (2014).
102. Strain, W. D. et al. Attenuated systemic microvascular function in men with coronary artery disease is associated with angina but not explained by atherosclerosis. Microcirculation 20, 670-677 (2013).
103. Murthy, V. L. et al. Coronary vascular dysfunction and prognosis in patients with chronic kidney disease. JACC Cardiovasc. Imaging 5, 1025-1034 (2012).
104. Nakanishi, K. et al. Prognostic values of coronary flow reserve in long-Term cardiovascular outcomes in patients with chronic kidney disease. Am. J. Cardiol. 112, 928-932 (2013).
105. Shaw, L. J., Bugiardini, R. & Merz, C. N. Women and ischemic heart disease: evolving knowledge. J. Am. Coll. Cardiol. 54, 1561-1575 (2009).
106. Khuddus, M. A. et al. An intravascular ultrasound analysis in women experiencing chest pain in the absence of obstructive coronary artery disease: a substudy from the National Heart, Lung and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). J. Interv. Cardiol. 23, 511-519 (2010).
107. Martino, S., Disch, D., Dowsett, S. A., Keech, C. A. & Mershon, J. L. Safety assessment of raloxifene over eight years in a clinical trial setting. Curr. Med. Res. Opin. 21, 1441-1452 (2005).
108. Barrett-Connor, E. et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med. 355, 125-137 (2006).
109. Anand, S. S. et al. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur. Heart J. 29, 932-940 (2008).
110. Stampfer, M. J., Hu, F. B., Manson, J. E., Rimm, E. B. & Willett, W. C. Primary prevention of coronary heart disease in women through diet and lifestyle. N. Engl. J. Med. 343, 16-22 (2000).
111. Samin, A., Nugent, L., Mehta, P. K., Shufelt, C. & Bairey Merz, C. N. Treatment of angina and coronary microvascular dysfunction. Curr. Treat. Options in Cardiovasc. Med. 12, 355-364 (2010).
112. Stone, N. J. et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129 (Suppl. 2), S1-S45 (2014).
113. Reriani, M. K. et al. Effects of statins on coronary and peripheral endothelial function in humans: a systematic review and meta-Analysis of randomized controlled trials. Eur. J. Cardiovasc. Prev. Rehabil. 18, 704-716 (2011).
114. Treasure, C. B. et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N. Engl. J. Med. 332, 481-487 (1995).
115. Ridker, P. M., MacFadyen, J., Libby, P. & Glynn, R. J. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Am. J. Cardiol. 106, 204-209 (2010).
116. Shahin, Y., Khan, J. A., Samuel, N. & Chetter, I. Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-Analysis of randomised controlled trials. Atherosclerosis 216, 7-16 (2011).
117. Pauly, D. F. et al. In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: a double-blind randomized study from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE). Am. Heart J. 162, 678-684 (2011).
118. Bavry, A. A. et al. Aldosterone inhibition and coronary endothelial function in women without obstructive coronary artery disease: an ancillary study of the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE). Am. Heart J. 167, 826-832 (2014).
119. Garg, R. et al. Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes. Diabetes 64, 236-242 (2015).
120. Fraker, T. D. Jr et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. J. Am. Coll. Cardiol. 50, 2264-2274 (2007).
121. Heidenreich, P. A. et al. Meta-Analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA 281, 1927-1936 (1999).
122. Bugiardini, R., Borghi, A., Biagetti, L. & Puddu, P. Comparison of verapamil versus propranolol therapy in syndrome X. Am. J. Cardiol. 63, 286-290 (1989).
123. Lanza, G. A., Colonna, G., Pasceri, V. & Maseri, A. Atenolol versus amlodipine versus isosorbide-5-mononitrate on anginal symptoms in syndrome X. Am. J. Cardiol. 84, 854-856 (1999).
124. Kayaalti, F. et al. Effects of nebivolol therapy on endothelial functions in cardiac syndrome X. Heart Vessels 25, 92-96 (2010).
125. Togni, M. et al. Does the beta-blocker nebivolol increase coronary flow reserve? Cardiovasc. Drugs Ther. 21, 99-108 (2007).
126. Cannon, R. O. 3rd, Watson, R. M., Rosing, D. R. & Epstein, S. E. Efficacy of calcium channel blocker therapy for angina pectoris resulting from small-vessel coronary artery disease and abnormal vasodilator reserve. Am. J. Cardiol. 56, 242-246 (1985).
127. Thadani, U. Current medical management of chronic stable angina. J. Cardiovasc. Pharmacol. Ther. 9 (Suppl. 1), S11-S29 (2004).
128. Opie, L. H. Calcium channel antagonists in the management of anginal syndromes: changing concepts in relation to the role of coronary vasospasm. Prog. Cardiovasc. Dis. 38, 291-314 (1996).
129. Timmis, A. D., Chaitman, B. R. & Crager, M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur. Heart J. 27, 42-48 (2006).
130. Chaitman, B. R. et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 291, 309-316 (2004).
131. Chaitman, B. R. et al. Anti-ischemic effects and long-Term survival during ranolazine monotherapy in patients with chronic severe angina. J. Am. Coll. Cardiol. 43, 1375-1382 (2004).
132. Belardinelli, L., Shryock, J. C. & Fraser, H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 92 (Suppl. 4), iv6-iv14 (2006).
133. Hemingway, H. et al. Incidence and prognostic implications of stable angina pectoris among women and men. JAMA 295, 1404-1411 (2006).
134. Holubkoy, R. et al. Angina 1 year after percutaneous coronary intervention: a report from the NHLBI Dynamic Registry. Am. Heart J. 144, 826-833 (2002).
135. Johnson, B. D. et al. Prognosis in women with myocardial ischemia in the absence of obstructive coronary artery disease: results from the National Institutes of Health-National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 109, 2993-2999 (2004).
136. Pepine, C. J. Ischemic heart disease in women: facts and wishful thinking. J. Am. Coll. Cardiol. 43, 1727-1730 (2004).
137. Pepine, C. J. Ischemic heart disease in women. J. Am. Coll. Cardiol. 47 (Suppl.), S1-S3 (2006).
138. Wenger, N. K., Chaitman, B. & Vetrovec, G. W. Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials. Am. J. Cardiol. 99, 11-18 (2007).
139. Skalidis, E. I., Hamilos, M. I., Chlouverakis, G., Zacharis, E. A. & Vardas, P. E. Ivabradine improves coronary flow reserve in patients with stable coronary artery disease. Atherosclerosis 215, 160-165 (2011).
140. Villano, A. et al. Effects of ivabradine and ranolazine in patients with microvascular angina pectoris. Am. J. Cardiol. 112, 8-13 (2013).
141. Emdin, M, Picano, E., Lattanzi, F. & L'Abbate, A. Improved exercise capacity with acute aminophylline administration in patients with syndrome X. J. Am. Coll. Cardiol. 14, 1450-1453 (1989).
142. Chen, J. W., Hsu, N. W., Wu, T. C., Lin, S. J. & Chang, M. S. Long-Term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am. J. Cardiol. 90, 974-982 (2002).
143. Bøtker, H. E., Sonne, H. S., Schmitz, O. & Nielsen, T. T. Effects of doxazosin on exercise-induced angina pectoris, ST-segment depression, and insulin sensitivity in patients with syndrome X. Am. J. Cardiol. 82, 1352-1356 (1998).
144. Chen, J. W. et al. Effects of short-Term treatment of nicorandil on exercise-induced myocardial ischemia and abnormal cardiac autonomic activity in microvascular angina. Am. J. Cardiol. 80, 32-38 (1997).
145. Vicari, R. M. et al. Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. J. Am. Coll. Cardiol. 46, 1803-1811 (2005).
146. Denardo, S. J. et al. Effect of phosphodiesterase type 5 inhibition on microvascular coronary dysfunction in women: a Women's Ischemia Syndrome Evaluation (WISE) ancillary study. Clin. Cardiol. 34, 483-487 (2011).
147. Maddox, T. M. et al. Utilization of secondary prevention therapies in patients with nonobstructive coronary artery disease identified during cardiac catheterization: insights from the National Cardiovascular Data Registry Cath-PCI Registry. Circ. Cardiovasc. Qual. Outcomes 3, 632-641 (2010).
148. Kronhaus, K. D. & Lawson, W. E. Enhanced external counterpulsation is an effective treatment for syndrome X. Int. J. Cardiol. 135, 256-257 (2009).
149. Di Pede, F. et al. Immediate and long-Term clinical outcome after spinal cord stimulation for refractory stable angina pectoris. Am. J. Cardiol. 91, 951-955 (2003).
150. van Peski-Oosterbaan, A. S. et al. Cognitive-behavioral therapy for noncardiac chest pain: a randomized trial. Am. J. Med. 106, 424-429 (1999).
151. Chauhan, A. et al. Effect of transcutaneous electrical nerve stimulation on coronary blood flow. Circulation 89, 694-702 (1994).
152. Lanza, G. A. et al. Effect of spinal cord stimulation on spontaneous and stress-induced angina and ischemic-like ST-segment depression in patients with cardiac syndrome X. Eur. Heart J. 26, 983-989 (2005).
153. Anderson, J. L. et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 116, 148-304 (2007).
154. Asbury, E. A., Kanji, N., Ernst, E, Barbir, M. & Collins, P. Autogenic training to manage symptomology in women with chest pain and normal coronary arteries. Menopause 16, 60-65 (2009).